TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Janssons Immunbiologiska AB JIBA
Closing information (x1000 EUR)
Closing information | 2023/12 | 2022/12 | 2021/12 |
Turnover | 561 | 555 | 640 |
Financial expenses | 0 | 1 | 1 |
Earnings before taxes | 108 | 108 | 201 |
EBITDA | 108 | 108 | 202 |
Total assets | 296 | 296 | 252 |
Current assets | 296 | 296 | 252 |
Current liabilities | 50 | 54 | 81 |
Equity capital | 245 | 242 | 171 |
- share capital | 9 | 9 | 10 |
Employees (average) | 2 | 2 | 5 |
Financial ratios
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Solvency | 82.8% | 81.8% | 67.9% |
Turnover per employee | 280 | 278 | 128 |
Profit as a percentage of turnover | 19.3% | 19.5% | 31.4% |
Return on assets (ROA) | 36.5% | 36.8% | 80.2% |
Current ratio | 592.0% | 548.1% | 311.1% |
Return on equity (ROE) | 44.1% | 44.6% | 117.5% |
Change turnover | 5 | -33 | -55 |
Change turnover % | 1% | -6% | -8% |
Chg. No. of employees | 0 | -3 | 0 |
Chg. No. of employees % | 0% | -60% | 0% |
Total value of public sale
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Total value of public sale | 0 | 0 | 0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.